×
<- Back

Update on Pharmacotherapy for Pulmonary Hypertension

  • : Online

Pulmonary arterial hypertension (PAH) is a rare disease with a poor prognosis if not treated. Pharmacological treatment options for PAH have increased significantly over the past 10 years, with availability of intravenous, oral and inhaled drugs targeting the nitric oxide, endothelin and prostacyclin pathways.

This module includes an evidence-based overview of PAH treatment as applied to clinical practice, focusing on Group 1 and Group 4 PH (for which there is good evidence for pharmacological treatment).

Learning Outcomes

  • Recognise that PAH is a rare disease with a poor prognosis if not treated
  • Become familiar with several new oral drugs beneficial in treating PAH, impacting future treatments
  • Provider name

    Medical Journal of Australia

    Provider number

    N/A

    Type

    Reading: journal; textbook; book; literature review

    Duration

    1h : 0m

    CPD Points/Hours

    MBA: 1h : 0m

    Topic

    Cardiovascular Diseases

    Audience

    Medical Practitioner, Medical Student, Doctor-in-Training, Non-Vocationally Registered, Nurse / Midwife, Pharmacist, Podiatrist, Researcher, Retired, Specialist - Other, Specialist General Practitioner

    Delivery
    Title
    Update on Pharmacotherapy for Pulmonary Hypertension
    Interest Areas / Topics Covered
    Pulmonary care, Respiratory Medicine
    Location
    Provider Type
    Education Provider
    Duration
    1 hour
    CPD Points
    MBA: 1h : 0m
    Price
    Free
    Location
    Online
    Contact Phone
    Log in into view this field.
    Cover Picture 257_update_on_pharmacotherapy_for_pulmonary_hypertension1601529938.png
    63 Views
    Similar Listings
    HealthcareLink